Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04251910
PHASE1/PHASE2

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

Sponsor: BioXcel Therapeutics Inc

View on ClinicalTrials.gov

Summary

This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.

Official title: A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia

Key Details

Gender

All

Age Range

65 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2019-12-27

Completion Date

2022-01-24

Last Updated

2026-06-03

Healthy Volunteers

No

Interventions

DRUG

Sublingual film containing Dexmedetomidine

Sublingual film containing Dexmedetomidine

DRUG

Sublingual Placebo Film

Sublingual placebo film that matches BXCL501

Locations (5)

BioXcel Clinical Research Site

Homestead, Florida, United States

BioXcel Clinical Research Site

Miami Lakes, Florida, United States

BioXcel Clinical Research Site

Springfield, Massachusetts, United States

BioXcel Clinical Research Site

Caro, Michigan, United States

BioXcel Clinical Research Site

Toms River, New Jersey, United States